Tricida (TCDA) Granted Additional U.S. Patent Covering Composition of Matter of Veverimer
- Wall Street slides on report of Biden's plan to almost double capital gains tax
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Credit Suisse (CS) Falls 6% on 'Unacceptable Loss' as Exposure to Archegos Grew to More Than $20 Billion, Set to Raise Over $2 Billion to Support Liquidity
- U.S. weekly jobless claims hit 13-month low; home sales tumble
- Cathie Wood's ARK Buys Over 5M Shares of Skillz (SKLZ), Nearly 3M Shares of IPO UiPath (PATH)
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced today that U.S. patent number 10,934,380, entitled “CROSSLINKED POLY(ALLYLAMINE) POLYMER COMPOSITIONS” has issued from the United States Patent and Trademark Office. The newly issued patent covers additional composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio, which is solely owned by the company, to a total of 210 patents in 49 different countries, including two previously issued U.S. composition of matter patents and four issued U.S. method of treatment patents which provide protection to 2034. In addition, Tricida holds three issued European Patent Office patents providing patent protection until 2034 and two additional issued patents providing protection until 2035 in Europe, as well as patent protection expected to provide protection for veverimer until at least 2034 in Australia, China, Hong Kong, Israel, Japan, Mexico and certain other markets. Tricida solely owns other patent applications relating to veverimer that are currently pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Republic of Korea, Russia, and the United States.
“This new composition of matter patent will enable us to fully capitalize on veverimer’s U.S. potential into 2038,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive Officer and President. “While our focus today is on the continued successful execution of the VALOR-CKD trial, we are not losing site of the commercial opportunity for veverimer. This patent adds four years of additional patent protection to our timeline to obtain the full value of veverimer.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MyMD Pharmaceuticals (MYMD) Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds
- Vertex Pharma (VRTX) and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
- Amarin (AMRN) Receives Great Britain Marketing Authorization for VAZKEPA from MHRA
Create E-mail Alert Related CategoriesCorporate News, Litigation
Related EntitiesEarnings, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!